Multiple Sclerosis — Research Summary
Printed from RareWays (rareways.com.au) on 10 June 2026
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
Emerging role of cell membrane-coated nanoparticles in targeted therapy for brain disorders.
Kumari Vaishnavi et al. — Biomaterials advances (1 July 2026)
https://pubmed.ncbi.nlm.nih.gov/41880816/
- 2.
RXR Gamma Enables Oligodendrocyte Differentiation by Suppressing Sonic Hedgehog Signaling.
Baldassarro Vito Antonio et al. — Glia (1 June 2026)
https://pubmed.ncbi.nlm.nih.gov/41934103/
- 3.
Pediatric Optic Neuritis: An Update on Diagnosis and Management.
Deyabat Osama Al et al. — Neurologic clinics (1 May 2026)
https://pubmed.ncbi.nlm.nih.gov/41922038/
- 4.
Updates on Imaging Features of Optic Neuritis and Mimicking Syndromes.
Malkawi Lna et al. — Neurologic clinics (1 May 2026)
https://pubmed.ncbi.nlm.nih.gov/41922033/
- 5.
Updates on the Acute and Maintenance Management of Optic Neuritis Including Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorder, and Myelin Oligodendrocyte Glycoprotein Antibody Disease.
Alchaki Abdul Rahman — Neurologic clinics (1 May 2026)
https://pubmed.ncbi.nlm.nih.gov/41922028/
Clinical Trials — Currently Recruiting (Australia)
Ask your doctor whether you or your child may be eligible for any of these trials.
- 1.
A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity
Recruiting — Phase 2 — Celgene
https://clinicaltrials.gov/study/NCT06782490
- 2.
An Open-label Study to Assess the Safety, Efficacy, and Cellular Kinetics of YTB323 in Relapsing Multiple Sclerosis
Recruiting — Phase 1 — Novartis Pharmaceuticals
https://clinicaltrials.gov/study/NCT06617793
- 3.
Open-label, Multi-center, Phase I/II Study to Assess Safety, Disease Progression and Cellular Kinetics Following YTB323 Administration in Participants With Non-active Progressive Multiple Sclerosis (PMS)
Recruiting — Phase 1 — Novartis Pharmaceuticals
https://clinicaltrials.gov/study/NCT06675864
- 4.
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
Recruiting — Phase 3 — Novartis Pharmaceuticals
https://clinicaltrials.gov/study/NCT07225504
- 5.
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)
Recruiting — Phase 2 — Hoffmann-La Roche
https://clinicaltrials.gov/study/NCT07282574
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Multiple Sclerosis
Multiple Sclerosis is a chronic autoimmune disease of the central nervous system in which the immune system attacks the myelin sheath covering nerve fibres. It affects approximately 26,000 Australians and is the most common neurological condition in young adults. Symptoms vary widely and can include fatigue, vision problems, numbness, and difficulty walking.
Most Recent Research
Brain disorders, including neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, and Huntington's disease, as well as conditions like multiple sclerosis and ischemic stroke, represent a significant global health burden. These disorders are often marked by progressive neuronal degeneration, cognitive impairment, and motor dysfunction. Effective therapeutic intervention remains a challenge due to the protective but restrictive nature of blood-CNS barriers, particularly the blood-brain barrier (BBB), which limits drug delivery to the brain. Nanotechnology-based drug delivery systems have emerged as promising solutions for addressing these barriers. However, issues such as limited biocompatibility, cytotoxicity, and suboptimal pharmacokinetics still hinder their widespread application. Cell membrane-coated nanoparticles (CMCNPs) offer a novel approach to overcome these challenges. These biomimetic nanocarriers integrate natural cell membranes sourced from red blood cells, platelets, or stem cells, with nanoparticles, enhancing biocompatibility, immune evasion, and BBB penetration. This review provides a comprehensive overview of recent advances in CMCNPs for brain disorders, highlighting their design, fabrication methods, and therapeutic potential. The unique properties of CMCNPs, such as prolonged systemic circulation, targeted drug delivery, and enhanced BBB permeability, make them promising candidates for neuroprotective and theranostic applications.
Common Questions
What is Multiple Sclerosis?
Multiple Sclerosis is a chronic autoimmune disease of the central nervous system in which the immune system attacks the myelin sheath covering nerve fibres. It affects approximately 26,000 Australians and is the most common neurological condition in young adults. Symptoms vary widely and can include fatigue, vision problems, numbness, and difficulty walking.
How many clinical trials are available for Multiple Sclerosis?
RareWays currently indexes 2723 clinical trials for Multiple Sclerosis, of which 405 are actively recruiting. Trial availability changes as new studies are registered — check the trials tab for current status.
Where does the research data for Multiple Sclerosis come from?
RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is updated regularly by Rocky, RareWays' automated research engine. All articles and trials link directly to their original sources.
Get research updates
Monthly email when new findings are published for Multiple Sclerosis.
No spam. Unsubscribe any time. Not medical advice.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.